← All upcoming FDA decisions

Joenja (leniolisib) for Activated PI3K delta syndrome (APDS), children 4 to 11

Pharming · sNDA
Approved
The FDA approved this application. Approval is the starting line, not the finish: our guide to what happens in the 90 days after a rare disease approval walks through specialty pharmacies, insurance review, and how families shorten the wait.

What the FDA decided

The FDA approved Pharming's sNDA for Joenja (leniolisib) in Activated PI3K delta syndrome (APDS), children 4 to 11. Approved September 11, 2026 as the first treatment for APDS in children aged 4 to 11 who weigh at least 27 kg (about 60 pounds), with weight-based dosing. Joenja was first approved in 2023 for ages 12 and up. The pediatric approval rests on an 8-patient open-label safety and pharmacokinetic study rather than a new efficacy trial.

Frequently asked questions

When will the FDA decide on Joenja?

The FDA has already decided: the application was approved. See the outcome details above.

What is Joenja being reviewed for?

Pharming submitted a sNDA for Joenja in Activated PI3K delta syndrome (APDS), children 4 to 11. Approved September 11, 2026 as the first treatment for APDS in children aged 4 to 11 who weigh at least 27 kg (about 60 pounds), with weight-based dosing. Joenja was first approved in 2023 for ages 12 and up. The pediatric approval rests on an 8-patient open-label safety and pharmacokinetic study rather than a new efficacy trial.

What happens after the Joenja decision?

If approved, availability is not immediate: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. If the FDA issues a complete response letter, the application was not approved in its current form; CRLs are often about manufacturing or data presentation rather than efficacy, and sponsors frequently resubmit. This page updates with the outcome either way.

Where this date comes from

The FDA does not publish PDUFA dates; companies disclose them. This one comes from FDA approval notice. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.